No Clinically Significant Drug Interaction Between Amoxicillin and Atorvastatin
Amoxicillin does not have a clinically significant drug interaction with atorvastatin and can be safely co-administered without dose adjustments.
Evidence Analysis
The provided evidence extensively discusses statin drug interactions, particularly focusing on medications that inhibit CYP3A4 (the primary metabolic pathway for atorvastatin) and various transporters (OATP1B1/1B3, P-gp, BCRP). Amoxicillin is notably absent from all guideline discussions of problematic drug interactions with statins 1.
Key Points from FDA Labeling
The FDA-approved atorvastatin labeling 2 specifically lists drugs that increase myopathy and rhabdomyolysis risk through CYP3A4 or transporter inhibition:
- Contraindicated or not recommended: Cyclosporine, gemfibrozil, certain antivirals (tipranavir/ritonavir, glecaprevir/pibrentasvir)
- Dose-limited combinations: Various antivirals, azole antifungals, macrolide antibiotics
- Amoxicillin is not mentioned in any of these categories
The Single Case Report Context
One case report 3 describes rhabdomyolysis in a patient taking atorvastatin who started amoxicillin-clavulanic acid. However, this isolated case has significant limitations:
- Single case report (lowest level of evidence)
- No established mechanism: Amoxicillin is not a CYP3A4 inhibitor or transporter inhibitor
- Confounding factors: The patient may have had other risk factors for rhabdomyolysis (age 55, potentially other medications, underlying conditions)
- Temporal association does not prove causation
Pharmacologic Rationale
Amoxicillin's metabolic profile makes interaction unlikely:
- Not metabolized by CYP3A4
- Not a known inhibitor of CYP3A4, OATP1B1/1B3, P-gp, or BCRP
- Primarily renally excreted unchanged
- No shared metabolic pathways with atorvastatin
Clinical Recommendation
Prescribe amoxicillin and atorvastatin together without hesitation or dose modification. The absence of amoxicillin from comprehensive AHA guidelines on statin drug interactions 1 and FDA labeling 2 is compelling evidence that no clinically meaningful interaction exists.
Monitoring Considerations
While no specific monitoring is required for this combination, maintain standard vigilance for statin-related adverse effects in all patients:
- Unexplained muscle pain, tenderness, or weakness
- Dark-colored urine
- Unusual fatigue
These symptoms warrant checking creatine kinase levels, but this applies to all patients on statins, not specifically those receiving concurrent amoxicillin.
Contrast with Problematic Antibiotics
Macrolide antibiotics (clarithromycin, erythromycin) ARE problematic with atorvastatin due to CYP3A4 inhibition 2. Amoxicillin, as a beta-lactam antibiotic, has an entirely different pharmacologic profile and does not share this concern.